ATE431136T1 - Orale zubereitungen mit vorteilhaften zerfallseigenschaften - Google Patents

Orale zubereitungen mit vorteilhaften zerfallseigenschaften

Info

Publication number
ATE431136T1
ATE431136T1 AT01965637T AT01965637T ATE431136T1 AT E431136 T1 ATE431136 T1 AT E431136T1 AT 01965637 T AT01965637 T AT 01965637T AT 01965637 T AT01965637 T AT 01965637T AT E431136 T1 ATE431136 T1 AT E431136T1
Authority
AT
Austria
Prior art keywords
water
carmellose
sodium
disintegrant
granule
Prior art date
Application number
AT01965637T
Other languages
English (en)
Inventor
Kazuyuki Fujihara
Original Assignee
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18771855&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE431136(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dainippon Sumitomo Pharma Co filed Critical Dainippon Sumitomo Pharma Co
Application granted granted Critical
Publication of ATE431136T1 publication Critical patent/ATE431136T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
AT01965637T 2000-09-22 2001-09-14 Orale zubereitungen mit vorteilhaften zerfallseigenschaften ATE431136T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000288234 2000-09-22
PCT/JP2001/007983 WO2002024166A1 (fr) 2000-09-22 2001-09-14 Preparations orales dotees de bonnes caracteristiques de desagregation

Publications (1)

Publication Number Publication Date
ATE431136T1 true ATE431136T1 (de) 2009-05-15

Family

ID=18771855

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01965637T ATE431136T1 (de) 2000-09-22 2001-09-14 Orale zubereitungen mit vorteilhaften zerfallseigenschaften

Country Status (11)

Country Link
US (1) US7727553B2 (de)
EP (2) EP1327440B1 (de)
JP (1) JP4868695B2 (de)
AT (1) ATE431136T1 (de)
AU (1) AU2001286237A1 (de)
CA (2) CA2824077C (de)
DE (1) DE60138722D1 (de)
DK (1) DK1327440T5 (de)
ES (1) ES2325764T3 (de)
TW (2) TWI289062B (de)
WO (1) WO2002024166A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2685780T3 (es) 2002-08-22 2018-10-11 Sumitomo Dainippon Pharma Co., Ltd. Agente para el tratamiento de esquizofrenia
SE0203778D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
KR101113630B1 (ko) 2003-06-23 2012-02-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 노인성 치매 치료제
EP1726952A4 (de) 2004-02-20 2008-06-18 Dainippon Sumitomo Pharma Co Verfahren zum in-vivo-screening eines therapeutikums für eine gedächtnis-/lernfehlfunktion durch schizophrenie
KR101435199B1 (ko) 2005-05-18 2014-08-28 다이닛본 스미토모 세이야꾸 가부시끼가이샤 드록시도파를 함유하는 안정한 정제
SI1884242T1 (sl) 2005-05-26 2013-07-31 Dainippon Sumitomo Pharma Co., Ltd. Farmacevtski sestavek, ki vsebuje lurazidon
EP1891956B1 (de) * 2005-06-13 2012-08-29 Dainippon Sumitomo Pharma Co., Ltd. Zubereitung zur solubilisierung
US20100209503A1 (en) * 2005-08-10 2010-08-19 Yoichi Taniguchi Bitter Taste Masking Dosage Form
US20080274178A1 (en) * 2005-08-10 2008-11-06 Shionogi & Co., Ltd. Orally Disintegrating Tablet
EP1973531A2 (de) * 2006-01-02 2008-10-01 Rubicon Research Private Limited Pharmazeutische zusammensetzungen
AR065802A1 (es) * 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
AU2008318851B2 (en) 2007-10-31 2014-04-17 Mcneil-Ppc, Inc. Orally disintegrated dosage form
WO2009101940A1 (ja) 2008-02-11 2009-08-20 Dainippon Sumitomo Pharma Co., Ltd. 溶出性の改善された錠剤
WO2009151072A1 (ja) 2008-06-13 2009-12-17 大日本住友製薬株式会社 口腔内速崩壊錠及びその製造方法
AU2009292615B2 (en) * 2008-09-17 2015-12-03 Mylan Inc. Granulates, process for preparing them and pharmaceutical products containing them
US8858210B2 (en) 2009-09-24 2014-10-14 Mcneil-Ppc, Inc. Manufacture of variable density dosage forms utilizing radiofrequency energy
US8784781B2 (en) 2009-09-24 2014-07-22 Mcneil-Ppc, Inc. Manufacture of chewing gum product with radiofrequency
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
WO2012107890A2 (en) * 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Crystalline forms of lurasidone hydrochloride
US9433620B2 (en) * 2011-05-13 2016-09-06 Cadila Healthcare Limited Pharmaceutical compositions of lurasidone
EP2827767B1 (de) 2012-03-21 2020-09-30 Koninklijke Philips N.V. Verfahren und vorrichtung zur bereitstellung einer visuellen darstellung der schlafqualität auf der basis von ekg-signalen
US9445971B2 (en) 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
US9233491B2 (en) 2012-05-01 2016-01-12 Johnson & Johnson Consumer Inc. Machine for production of solid dosage forms
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
JP6007169B2 (ja) * 2012-11-30 2016-10-12 大原薬品工業株式会社 アリピプラゾール無水物を含有する固形製剤の製造方法
WO2014090386A1 (en) * 2012-12-11 2014-06-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Orally disintegrating tablet containing asenapine
JP6037824B2 (ja) * 2012-12-28 2016-12-07 ライオン株式会社 エトドラク含有固形製剤
JP2014129238A (ja) * 2012-12-28 2014-07-10 Lion Corp エトドラク含有固形製剤
RU2712267C2 (ru) 2014-01-10 2020-01-28 Джонсон энд Джонсон Консьюмер Инк. Способ изготовления таблеток с использованием радиочастотного излучения и частиц с поглощающим покрытием
WO2016012898A1 (en) 2014-07-25 2016-01-28 Lupin Limited Oral pharmaceutical composition of lurasidone
WO2016139683A2 (en) * 2015-03-05 2016-09-09 Jubilant Generics Limited Pharmaceutical compositions of lurasidone and process for preparing the same
US10966928B2 (en) 2016-03-25 2021-04-06 Universiteit Gent Oral dosage form
ES2883352T3 (es) 2016-03-25 2021-12-07 Univ Gent Forma de dosificación oral
JPWO2017170858A1 (ja) * 2016-03-31 2019-02-14 インターセプト ファーマシューティカルズ， インコーポレイテッド 溶出性に優れた経口製剤
CA3034995A1 (en) * 2016-08-31 2018-03-08 Sumitomo Dainippon Pharma Co., Ltd. Aqueous suspension preparation
US11260055B2 (en) 2017-01-11 2022-03-01 Piramal Enterprises Limited Oral pharmaceutical composition of lurasidone and preparation thereof
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
AT17300U3 (de) * 2020-12-03 2022-02-15 G L Pharma Gmbh Feste orale pharmazeutische Zusammensetzung
WO2023078366A1 (zh) * 2021-11-04 2023-05-11 上海博志研新药物技术有限公司 一种盐酸鲁拉西酮口溶膜组合物、其制备方法及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61148114A (ja) * 1984-11-15 1986-07-05 Teijin Ltd ニフエジピンの顆粒剤
JP2800953B2 (ja) * 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
JPH04305526A (ja) * 1991-03-28 1992-10-28 Morishita Roussel Kk 薬剤組成物
ZA939565B (en) 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for preparing low dose pharmaceutical products.
US5811120A (en) * 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5972383A (en) * 1994-03-02 1999-10-26 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
EP0839526A3 (de) * 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Festes pharmazeutisches Präparat mit schneller Auflösungs- oder Disintegrationeigenschaften
TW482675B (en) * 1997-01-31 2002-04-11 Green Cross Corp Compositions for oral administration containing pyridazinone compounds technical field of the invention
JP2001526212A (ja) * 1997-12-19 2001-12-18 スミスクライン・ビーチャム・コーポレイション 咀嚼分散性錠剤の製造法
US6465009B1 (en) 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
JP4438121B2 (ja) * 1998-04-27 2010-03-24 大正製薬株式会社 口腔内速崩錠及びその製造方法
KR100267576B1 (ko) * 1998-07-25 2000-11-01 허계성 활성성분을 분리함유한 츄잉 연질정제 및 그의 제조방법
JP2000086503A (ja) * 1998-09-07 2000-03-28 Pola Chem Ind Inc 錠剤医薬組成物
JP2000086509A (ja) 1998-09-14 2000-03-28 Taisho Yakuhin Kogyo Kk ソファルコン含有製剤の製造方法
US6245352B1 (en) * 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation

Also Published As

Publication number Publication date
CA2424001A1 (en) 2003-03-20
JPWO2002024166A1 (ja) 2004-01-29
EP1327440A4 (de) 2006-02-01
EP1974724A2 (de) 2008-10-01
US20040028741A1 (en) 2004-02-12
DK1327440T5 (da) 2009-09-07
US7727553B2 (en) 2010-06-01
TWI289062B (en) 2007-11-01
DK1327440T3 (da) 2009-06-08
ES2325764T3 (es) 2009-09-16
CA2424001C (en) 2013-10-22
CA2824077C (en) 2016-01-26
EP1327440A1 (de) 2003-07-16
EP1974724A3 (de) 2008-11-12
AU2001286237A1 (en) 2002-04-02
TW200524642A (en) 2005-08-01
JP4868695B2 (ja) 2012-02-01
DE60138722D1 (de) 2009-06-25
TWI289063B (en) 2007-11-01
WO2002024166A1 (fr) 2002-03-28
EP1327440B1 (de) 2009-05-13
CA2824077A1 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
DK1327440T3 (da) Orale præparater med gunstige nedbrydningsegenskaber
EP1884242A4 (de) Pharmazeutische zusammensetzung
EE05022B1 (et) Eelthelatineeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis ja hüdrofiilne kontrollitud vabanemisega preparaat
HUP9902808A2 (hu) 5-(2-(4-(1,2-Benzizotiazol-3-il)-1-piperazinil)-etil)-6-klór-1,3-dihidro-2-(1H)-indol-2-on (ziprazidon) mezilát-trihidrát sói, a vegyületek előállítása és dopamin D2 antagonistaként történő alkalmazása
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
ATE154239T1 (de) Sphäroidische arzneimittelformulierung
ZA992951B (en) N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders.
CA2395846A1 (en) Diazepan derivatives or salts thereof
TNSN01005A1 (en) GLYBURIDE COMPOSITION
RU96116411A (ru) Быстро распадающаяся готовая препаративная форма трамадола или соли трамадола
AU2006248593A1 (en) Dispersible bosertan tablet
DE69908626D1 (de) Orale kombination von lufenuron und nitenpyram gegen flöhe
DE60233552D1 (de) Fenofibrattabletten
WO2004014343A1 (en) Storage stable tablets of fosinopril sodium
TR200202557T1 (tr) Esmolol formülasyonu
EP1645273A3 (de) Neue Verwendung von (R)-(-)-2-(5-(4-Fluorophenyl)-3-Pyridylmethylaminomethyl)-Chromane und ihrer physiologisch verträglichen Salze
CA2457982A1 (en) Use of nefiracetam for treating neurodegeneration
NO329213B1 (no) Umiddelbar frigivelses medisinske sammensetninger for oral anvendelse
EA199900226A1 (ru) Фармацевтические композиции для лечения вирусных заболеваний
NO20033855D0 (no) Fremgangsmåte ved fremstilling av farmasöytiske tabletter inneholdende paroxetinhydrokloridanhydrat
WO2005021002A1 (en) Pharmaceutical formulation comprising a pyrimidine-a-one derivative coated with an enteric polymer
AU7547100A (en) Alkylpiperidi nylbenzo [d] isoxazole derivatives having psychotropic activity, pharmaceutical compositions containing the same, and a process for the preparation of the active ingredient
WO2008016165A3 (en) Liquid preparation
WO2005034954A3 (en) Pharmaceutical compositions of paroxetine containing microcrystalline cellulose, prepared by wet granulation
NO20031030L (no) Nye krystaller av N-hydroksy-2(S)-metyl-5-etoksymetoksy-4(S)- [N-(4-fenoksyfenylkarbonyl)amino]pentanamid, fremgangsmåte for deresfremstilling og medisinerinneholdende krystallene som den aktive bestanddel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties